Showing results (331-340 of 342) with videos related to
Sort By:
Pageof 35
Ebiomedicine|February 10, 2018
Systems Signatures Reveal Unique Remission-path of Type 2 Diabetes Following Roux-en-Y Gastric Bypass SurgeryQing-Run Li, Zi-Ming Wang, Nicolai J Wewer Albrechtsen, et al.Cell Host & Microbe|December 6, 2016
Genesis, Evolution and Prevalence of H5N6 Avian Influenza Viruses in ChinaYuhai Bi, Quanjiao Chen, Qianli Wang, et al.Research Square|May 19, 2025
Spatially Resolved Panoramic in vivo CRISPR Screen via Perturb-DBiTRong Fan, Alev Baysoy, Xiaolong Tian, et al.The Lancet. Infectious Diseases|October 18, 2020
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trialShengli Xia, Yuntao Zhang, Yanxia Wang, et al.Cell|August 12, 2020
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2Hui Wang, Yuntao Zhang, Baoying Huang, et al.Biorxiv : the Preprint Server for Biology|April 17, 2026
Human Lymph Node Cellular Senescence Atlas Reveals Age-Dependent Alteration in Germinal Center B Cell Function and NichesNegin Farzad, Archibald Enninful, Yao Lu, et al.Cell Press Blue|July 28, 2026
A spatial multi-omics atlas of immunosenescence reveals germinal-center B cell dysfunction in human lymph nodesNegin Farzad, Archibald Enninful, Yao Lu, et al.Nature Biotechnology|June 11, 2026
Large-scale, spatially resolved panoramic CRISPR screening in native tissue environments using Perturb-DBiTAlev Baysoy, Xiaolong Tian, Paul Renauer, et al.The Lancet. Infectious Diseases|September 18, 2021
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trialShengLi Xia, YunTao Zhang, YanXia Wang, et al.China CDC Weekly|October 1, 2021
COVID-19 Outbreak Caused by Contaminated Packaging of Imported Cold-Chain Products - Liaoning Province, China, July 2020Huilai Ma, Jianqun Zhang, Ji Wang, et al.Pageof 35